Best MicroCap, Small Cap and Emerging Stocks to Buy - J Charles Assets
We search for the smart new growing companies to invest in with stock deals to watch in pharmacuetical and digital verticals.
strong fundamentals..not sure why its notgoing beyond 10$ mark
I HOPE THIS COMPANY GIVES SHAREHOLDERS MORE INFO. AS TO WHAT IS "REALLY" GOING ON SINCE I WOULD LIKE TO MAKE AN INVESTMENT HERE! SOLD MY "UVE" TODAY & HAVE LOTS OF CASH AVAILABLE. I RECOMMENDED THAT STOCK ON SEVERAL MESSAGE BOARDS RECENTLY!
Got a great report from http://yugestocks.com/?s=NAII about $NAII. I did have to subscribe but it was worth the time. Thank you guys for the tip! Barber's laws of backpacking: 1) the integral of the gravitational potential taken around any loop trail you choose to hike Day trading investing.
Yuge Stocks: Trading Stocks and Making Money
Stock alerts from the Yuge Stocks. Stock trading, making money and always looking for the next big money maker.
Big news this week. Getting Carnosyn into beverage and other avenues is huge. I would expect more good news to come. Very undervalued. Management needs to tell their story.
Is the news this morning as good as it seems?? In the PR they say this significantly lengthens the patent coverage on original CarnoSyn til 2023. That can't be the instant release Carnosyn patent that expires this year? If so, the stock should be up several dollars today.
CARLSBAD, Calif., April 3, 2017 /PRNewswire/ -- Natural Alternatives International, Inc. ("NAI") (NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, announced today that the U.S. Patent and Trademark Office has issued a Notice of Allowance of a patent application directed to a broad range of improved methods of beta-alanine intake. These 28 allowed patent claims target such benefits as delaying muscle fatigue, increasing anaerobic capacity, increasing muscle strength and increasing muscle endurance. This patent when issued will not only become part of NAI's extensive global portfolio covering its CarnoSyn® beta-alanine and SR CarnoSyn® product, but more importantly, significantly lengthens the patent coverage around its original CarnoSyn® beta-alanine to 2023. Following this Notice of Allowance NAI intends to seek a significant number of additional patent claims to further broaden its intellectual property protection.
Mark A. LeDoux, NAI's CEO and Chairman of the Board, said that "NAI is very excited by the addition of this important intellectual property related to a broad range of improved methods of beta-alanine intake. We believe this new patent continues to strengthen our worldwide portfolio of intellectual property related to our branded CarnoSyn® beta-alanine. Moreover, these patent rights will not expire until 2023, which gives NAI and its dedicated licensees the benefit of offering products that include CarnoSyn® beta-alanine and the patent portfolio surrounding it. These new patent rights further demonstrate our commitment and significant investment in the CarnoSyn® beta-alanine business."
Interesting form 4 filed today. About six officers and directors exercised their $0 options yet none sold any shares to cover their impending tax bills...bullish
Also, the company extending their line of credit with Wells Fargo for another year even tho it wasn't set to mature until 2019
Natural Alternatives International NASDAQ : NAII Correlation Histogram
X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks May-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is -0.4 In other words, the correlation coefficient of the other stoc
Why oh why did i buy this at 13.50?
Couple of new job postings on the NAII website this month. Including one for a Formulator yesterday. Good to see they're still hiring. Hopefully that means business is picking up as we head into fiscal Q4, just as the CEO expected.
Found a great no fee daytrading newsletter, vist T0pMarketGaIners.c0m and sign up...so glad I did
never did hear from them (expected it) & i indicated previously that cos. that ignore shareholders concerns usually "DRIFT" lower!
Strange that this company does so little for investor communications. No conference calls, no investor conferences and very shallow press releases will prevent any real interest by small cap investment managers. Analysts need questions answered in a public forum.
I see management often stupidly shooting themselves in the foot due to sheer naivety on their part. I guess they like things that way they are.
I guess $1,000 a quarter and an extra hour of effort each month is too much for certain people.
i mentioned that i called the company the other day & was told one of the two officers i mentioned would contact me since neither was available & i also indicated that i really didn't expect them to do so -unless shareholder friendly! i would of asked them if they were considering to update analyst for a better understanding since many concerns were raised after their last report. evidently they don't see any concerns or could it be things are as bad as the price indicates?